Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Moreau, P. Mateos, M.-. Gonzalez Garcia, M.E. Einsele, H. De Stefano, V. Karlin, L. Lindsey-Hill, J. Besemer, B. Vincent, L. Kirkpatrick, S. Delforge, M. Perrot, A. van de Donk, N.W. Pawlyn, C. Manier, S. Leleu, X. Martinez-Lopez, J. Ghilotti, F. Diels, J. Morano, R. Albrecht, C. Strulev, V. Haddad, I. Pei, L. Kobos, R. Smit, J. Slavcev, M. Marshall, A. Weisel, K. (2024). Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Adv ther, Vol.41 (2), pp. 696-715.  show abstract  full text

Hwang, A. Hayden, P. Pawlyn, C. McLornan, D. Garderet, L. (2024). The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Br j haematol, Vol.204 (4), pp. 1159-1175.  show abstract  full text

Maura, F. Rajanna, A.R. Ziccheddu, B. Poos, A.M. Derkach, A. Maclachlan, K. Durante, M. Diamond, B. Papadimitriou, M. Davies, F. Boyle, E.M. Walker, B. Hultcrantz, M. Silva, A. Hampton, O. Teer, J.K. Siegel, E.M. Bolli, N. Jackson, G.H. Kaiser, M. Pawlyn, C. Cook, G. Kazandjian, D. Stein, C. Chesi, M. Bergsagel, L. Mai, E.K. Goldschmidt, H. Weisel, K.C. Fenk, R. Raab, M.S. Van Rhee, F. Usmani, S. Shain, K.H. Weinhold, N. Morgan, G. Landgren, O. (2024). Genomic Classification and Individualized Prognosis in Multiple Myeloma. J clin oncol, Vol.42 (11), pp. 1229-1240.  show abstract  full text

Pawlyn, C. Schjesvold, F.H. Cairns, D.A. Wei, L.J. Davies, F. Nadeem, O. Abdulhaq, H. Mateos, M.-. Laubach, J. Weisel, K. Ludwig, H. Rajkumar, S.V. Sonneveld, P. Jackson, G. Morgan, G. Richardson, P.G. (2024). Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood cancer j, Vol.14 (1), p. 134.  show abstract  full text

Giles, H.V. Drayson, M.T. Kishore, B. Pawlyn, C. Kaiser, M. Cook, G. de Tute, R. Owen, R.G. Cairns, D. Menzies, T. Davies, F.E. Morgan, G.J. Pratt, G. Jackson, G.H. (2024). Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood cancer j, Vol.14 (1), p. 50.  show abstract  full text

Panopoulou, A. Easdale, S. Ethell, M. Nicholson, E. Potter, M. Giotas, A. Woods, H. Thornton, T. Pawlyn, C. Boyd, K.D. Kaiser, M.F. (2023). Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients. Hemasphere, Vol.7 (2), p. e831.  show abstract  full text

Jenner, M.W. Pawlyn, C. Davies, F.E. Menzies, T. Hockaday, A. Olivier, C. Jones, J.R. Karunanithi, K. Lindsay, J. Kishore, B. Cook, G. Drayson, M.T. Kaiser, M.F. Owen, R.G. Gregory, W. Cairns, D.A. Morgan, G.J. Jackson, G.H. UK National Cancer Research Institute (NCRI) Haemato-oncology Clinical Studies Group, (2023). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. Br j haematol, Vol.201 (2), pp. 267-279.  show abstract  full text

Mian, H. McCurdy, A. Giri, S. Grant, S. Rochwerg, B. Winks, E. Rosko, A.E. Engelhardt, M. Pawlyn, C. Cook, G. Jackson, G. Bringhen, S. Facon, T. Larocca, A. Zweegman, S. Wildes, T.M. (2023). The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood cancer j, Vol.13 (1), p. 6.  show abstract  full text

Moreau, P. van de Donk, N.W. Delforge, M. Einsele, H. De Stefano, V. Perrot, A. Besemer, B. Pawlyn, C. Karlin, L. Manier, S. Leleu, X. Weisel, K. Ghilotti, F. Diels, J. Elsada, A. Morano, R. Strulev, V. Pei, L. Kobos, R. Smit, J. Slavcev, M. Mateos, M.-. (2023). Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Adv ther, Vol.40 (5), pp. 2412-2425.  show abstract

Panopoulou, A. Cairns, D.A. Holroyd, A. Nichols, I. Cray, N. Pawlyn, C. Cook, G. Drayson, M. Boyd, K. Davies, F.E. Jenner, M. Morgan, G.J. Owen, R. Houlston, R. Jackson, G. Kaiser, M.F. (2023). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood, Vol.141 (14), pp. 1666-1674.  show abstract  full text

Jones, J.R. Cairns, D.A. Menzies, T. Pawlyn, C. Davies, F.E. Sigsworth, R. Brioli, A. Jenner, M.W. Kaiser, M.F. Olivier, C. Reed, M. Drayson, M.T. Owen, R.G. Boyd, K.D. Cook, G. Morgan, G.J. Jackson, G.H. NCRI Haemato-Oncology CSG, (2023). Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. Eclinicalmedicine, Vol.62, p. 102099.  show abstract  full text

Richardson, P.G. Trudel, S. Popat, R. Mateos, M.-. Vangsted, A.J. Ramasamy, K. Martinez-Lopez, J. Quach, H. Orlowski, R.Z. Arnao, M. Lonial, S. Karanes, C. Pawlyn, C. Kim, K. Oriol, A. Berdeja, J.G. Rodríguez Otero, P. Casas-Avilés, I. Spirli, A. Poon, J. Li, S. Gong, J. Wong, L. Lamba, M. Pierce, D.W. Amatangelo, M. Peluso, T. Maciag, P. Katz, J. Pourdehnad, M. Bahlis, N.J. CC-92480-MM-001 Study Investigators, (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N engl j med, Vol.389 (11), pp. 1009-1022.  show abstract

Pawlyn, C. Cairns, D. Menzies, T. Jones, J. Jenner, M. Cook, G. Boyd, K. Drayson, M. Kaiser, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Davies, F. (2022). Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, Vol.107 (1), pp. 231-242.  show abstract  full text

de Tute, R.M. Pawlyn, C. Cairns, D.A. Davies, F.E. Menzies, T. Rawstron, A. Jones, J.R. Hockaday, A. Henderson, R. Cook, G. Drayson, M.T. Jenner, M.W. Kaiser, M.F. Gregory, W.M. Morgan, G.J. Jackson, G.H. Owen, R.G. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J clin oncol, Vol.40 (25), pp. 2889-2900.  show abstract  full text

Coulson, A.B. Royle, K.-. Pawlyn, C. Cairns, D.A. Hockaday, A. Bird, J. Bowcock, S. Kaiser, M. de Tute, R. Rabin, N. Boyd, K. Jones, J. Parrish, C. Gardner, H. Meads, D. Dawkins, B. Olivier, C. Henderson, R. Best, P. Owen, R. Jenner, M. Kishore, B. Drayson, M. Jackson, G. Cook, G. (2022). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. Bmj open, Vol.12 (6), p. e056147.  show abstract  full text

Caro, J. Cairns, D. Menzies, T. Boyle, E. Pawlyn, C. Cook, G. Kaiser, M. Walker, B.A. Owen, R. Jackson, G.H. Morgan, G.J. Heaney, J. Drayson, M.T. Davies, F.E. (2022). Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clin lymphoma myeloma leuk, Vol.22 (4), pp. e279-e284.  show abstract

Davies, F.E. Pawlyn, C. Usmani, S.Z. San-Miguel, J.F. Einsele, H. Boyle, E.M. Corre, J. Auclair, D. Cho, H.J. Lonial, S. Sonneveld, P. Stewart, A.K. Bergsagel, P.L. Kaiser, M.F. Weisel, K. Keats, J.J. Mikhael, J.R. Morgan, K.E. Ghobrial, I.M. Orlowski, R.Z. Landgren, C.O. Gay, F. Caers, J. Chng, W.J. Chari, A. Walker, B.A. Kumar, S.K. Costa, L.J. Anderson, K.C. Morgan, G.J. (2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discov, Vol.3 (4), pp. 273-284.  show abstract  full text

Pawlyn, C. Khan, A.M. Freeman, C.L. (2022). Fitness and frailty in myeloma. Hematology am soc hematol educ program, Vol.2022 (1), pp. 337-348.  show abstract

Leleu, X. Martin, T. Weisel, K. Schjesvold, F. Iida, S. Malavasi, F. Manier, S. Chang-Ki Min, Ocio, E.M. Pawlyn, C. Perrot, A. Quach, H. Richter, J. Spicka, I. Yong, K. Richardson, P.G. (2022). Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann hematol, Vol.101 (10), pp. 2123-2137.  show abstract  full text

Cook, G. Pawlyn, C. Cairns, D.A. Jackson, G.H. (2022). Defining FiTNEss for treatment for multiple myeloma. Lancet healthy longev, Vol.3 (11), pp. e729-e730.

Agbuduwe, C. Iqbal, G. Cairns, D. Menzies, T. Dunn, J. Gregory, W. Kaiser, M. Owen, R. Pawlyn, C. Child, J.A. Davies, F. Morgan, G.J. Jackson, G.H. Drayson, M.T. Basu, S. (2022). Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. Blood adv, Vol.6 (17), pp. 5113-5123.  show abstract  full text

Ludwig, H. Boccadoro, M. Moreau, P. San-Miguel, J. Cavo, M. Pawlyn, C. Zweegman, S. Facon, T. Driessen, C. Hajek, R. Dimopoulos, M.A. Gay, F. Avet-Loiseau, H. Terpos, E. Zojer, N. Mohty, M. Mateos, M.-. Einsele, H. Delforge, M. Caers, J. Weisel, K. Jackson, G. Garderet, L. Engelhardt, M. van de Donk, N. Leleu, X. Goldschmidt, H. Beksac, M. Nijhof, I. Abildgaard, N. Bringhen, S. Sonneveld, P. (2021). Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, Vol.35 (1), pp. 31-44.  show abstract  full text

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Allotey, D. Shafeek, S. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. Clinical Studies Group, U.N. (2021). Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, Vol.106 (7), pp. 1957-1967.  show abstract  full text

Jackson, G.H. Pawlyn, C. Cairns, D.A. de Tute, R.M. Hockaday, A. Collett, C. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Rocci, A. Snowden, J.A. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Gregory, W.M. Kaiser, M.F. Owen, R.G. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2021). Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. Plos med, Vol.18 (1), p. e1003454.  show abstract  full text

Jackson, G.H. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Wilson, J. Taylor, C. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Kaiser, M.F. Owen, R.G. Gregory, W.M. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2021). Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br j haematol, Vol.192 (5), pp. 853-868.  show abstract  full text

Brown, S. Pawlyn, C. Tillotson, A.-. Sherratt, D. Flanagan, L. Low, E. Morgan, G.J. Williams, C. Kaiser, M. Davies, F.E. Jenner, M.W. Myeloma UK Early Phase Clinical Trial Network, (2021). Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clin lymphoma myeloma leuk, Vol.21 (3), pp. 154-161.e3.  show abstract

Bygrave, C. Pawlyn, C. Davies, F. Craig, Z. Cairns, D. Hockaday, A. Jenner, M. Cook, G. Drayson, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Kaiser, M. (2021). Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br j haematol, Vol.193 (3), pp. 551-555.  show abstract  full text

Bird, S. Panopoulou, A. Shea, R.L. Tsui, M. Saso, R. Sud, A. West, S. Smith, K. Barwood, J. Kaczmarek, E. Panlaqui, C. Kaiser, M. Stern, S. Pawlyn, C. Boyd, K. (2021). Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet haematol, Vol.8 (6), pp. e389-e392.  full text

Messiou, C. Porta, N. Sharma, B. Levine, D. Koh, D.-. Boyd, K. Pawlyn, C. Riddell, A. Downey, K. Croft, J. Morgan, V. Stern, S. Cheung, B. Kyriakou, C. Kaczmarek, P. Winfield, J. Blackledge, M. Oyen, W.J. Kaiser, M.F. (2021). Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol imaging cancer, Vol.3 (5), p. e210048.  show abstract  full text

Terpos, E. Raje, N. Croucher, P. Garcia-Sanz, R. Leleu, X. Pasteiner, W. Wang, Y. Glennane, A. Canon, J. Pawlyn, C. (2021). Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood adv, Vol.5 (3), pp. 725-736.  show abstract

Bird, S. Cairns, D. Menzies, T. Boyd, K. Davies, F. Cook, G. Drayson, M. Gregory, W. Jenner, M. Jones, J. Kaiser, M. Owen, R. Jackson, G. Morgan, G. Pawlyn, C. (2021). Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin lymphoma myeloma leuk, Vol.21 (10), pp. 667-675.  show abstract

Jones, J.R. Barber, A. Le Bihan, Y.-. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C.P. Wang, H. Kaiser, M.F. Jackson, G.H. Davies, F.E. Chopra, R. Morgan, G.J. Pawlyn, C. (2021). Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia, Vol.35 (10), pp. 3017-3020.  full text

Jones, J.R. Pawlyn, C. Jackson, G.H. (2021). Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert opin drug saf, Vol.20 (10), pp. 1137-1145.  show abstract

Ludwig, H. Sonneveld, P. Facon, T. San-Miguel, J. Avet-Loiseau, H. Mohty, M. Mateos, M.-. Moreau, P. Cavo, M. Pawlyn, C. Zweegman, S. Engelhardt, M. Driessen, C. Cook, G. Dimopoulos, M.A. Gay, F. Einsele, H. Delforge, M. Caers, J. Weisel, K. Jackson, G. Garderet, L. van de Donk, N. Leleu, X. Goldschmidt, H. Beksac, M. Nijhof, I. Schreder, M. Abildgaard, N. Hajek, R. Zojer, N. Kastritis, E. Broijl, A. Schjesvold, F. Boccadoro, M. Terpos, E. (2021). COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet haematol, Vol.8 (12), pp. e934-e946.  show abstract

Pawlyn, C. Cairns, D. Kaiser, M. Striha, A. Jones, J. Shah, V. Jenner, M. Drayson, M. Owen, R. Gregory, W. Cook, G. Morgan, G. Jackson, G. Davies, F. (2020). The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, Vol.34 (2), pp. 604-612.  show abstract  full text

Mian, H. Grant, S.J. Engelhardt, M. Pawlyn, C. Bringhen, S. Zweegman, S. Stege, C.A. Rosko, A.E. von Lilienfeld-Toal, M. Wildes, T.M. (2020). Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. J geriatr oncol, Vol.11 (5), pp. 764-768.  full text

Bird, S.A. Jackson, G.H. Pawlyn, C. (2020). Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clin hematol int, Vol.2 (2), pp. 59-68.  show abstract  full text

Rana, R. Cockwell, P. Drayson, M. Cook, M. Pratt, G. Cairns, D.A. Pawlyn, C. Jackson, G. Davies, F. Morgan, G. Pinney, J.H. (2020). Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood adv, Vol.4 (22), pp. 5836-5845.  show abstract

Bradbury, C.A. Craig, Z. Cook, G. Pawlyn, C. Cairns, D.A. Hockaday, A. Paterson, A. Jenner, M.W. Jones, J.R. Drayson, M.T. Owen, R.G. Kaiser, M.F. Gregory, W.M. Davies, F.E. Child, J.A. Morgan, G.J. Jackson, G.H. (2020). Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, Vol.136 (9), pp. 1091-1104.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Hockaday, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2019). Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet oncol, Vol.20 (1), pp. 57-73.  show abstract  full text

Pawlyn, C. Jackson, G.H. (2019). Physicians, paraproteins and progress: diagnosis and management of myeloma. Br j hosp med (lond), Vol.80 (2), pp. 91-98.  show abstract  full text

Cook, G. Royle, K.-. Pawlyn, C. Hockaday, A. Shah, V. Kaiser, M.F. Brown, S.R. Gregory, W.M. Child, J.A. Davies, F.E. Morgan, G.J. Cairns, D.A. Jackson, G.H. (2019). A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet haematol, Vol.6 (3), pp. e154-e166.  show abstract  full text

Jones, J.R. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C. Pawlyn, C. Rasche, L. Melchor, L. Cairns, D.A. Gregory, W.M. Johnson, D. Begum, D.B. Ellis, S. Sherborne, A.L. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Jackson, G.H. Davies, F.E. Greaves, M. Morgan, G.J. NCRI Haemato-Oncology CSG, (2019). Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, Vol.104 (7), pp. 1440-1450.  show abstract  full text

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Wilson, J.N. Jenner, M.W. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Russell, N.H. Gregory, W.M. Morgan, G.J. UK NCRI Haematological Oncology Clinical Studies Group, (2019). Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet haematol, Vol.6 (12), pp. e616-e629.  show abstract  full text

Pawlyn, C. Davies, F.E. (2019). Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood, Vol.133 (7), pp. 660-675.  show abstract  full text

Shah, V. Sherborne, A.L. Walker, B.A. Johnson, D.C. Boyle, E.M. Ellis, S. Begum, D.B. Proszek, P.Z. Jones, J.R. Pawlyn, C. Savola, S. Jenner, M.W. Drayson, M.T. Owen, R.G. Houlston, R.S. Cairns, D.A. Gregory, W.M. Cook, G. Davies, F.E. Jackson, G.H. Morgan, G.J. Kaiser, M.F. (2018). Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia, Vol.32 (1), pp. 102-110.  show abstract  full text

Gay, F. Jackson, G. Rosiñol, L. Holstein, S.A. Moreau, P. Spada, S. Davies, F. Lahuerta, J.J. Leleu, X. Bringhen, S. Evangelista, A. Hulin, C. Panzani, U. Cairns, D.A. Di Raimondo, F. Macro, M. Liberati, A.M. Pawlyn, C. Offidani, M. Spencer, A. Hájek, R. Terpos, E. Morgan, G.J. Bladé, J. Sonneveld, P. San-Miguel, J. McCarthy, P.L. Ludwig, H. Boccadoro, M. Mateos, M.-. Attal, M. (2018). Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. Jama oncol, Vol.4 (10), pp. 1389-1397.  show abstract

Pawlyn, C. Davies, F.E. (2018). Molecular profiling in myeloma. Hemasphere, Vol.2, pp. 118-120.

Pawlyn, C. Loehr, A. Ashby, C. Tytarenko, R. Deshpande, S. Sun, J. Fedorchak, K. Mughal, T. Davies, F.E. Walker, B.A. Morgan, G.J. (2018). Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. Leukemia, Vol.32 (7), pp. 1561-1566.  show abstract  full text

Fok, J.H. Hedayat, S. Zhang, L. Aronson, L.I. Mirabella, F. Pawlyn, C. Bright, M.D. Wardell, C.P. Keats, J.J. De Billy, E. Rye, C.S. Chessum, N.E. Jones, K. Morgan, G.J. Eccles, S.A. Workman, P. Davies, F.E. (2018). HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. Clin cancer res, Vol.24 (10), pp. 2395-2407.  show abstract  full text

Bødker, J.S. Brøndum, R.F. Schmitz, A. Schönherz, A.A. Jespersen, D.S. Sønderkær, M. Vesteghem, C. Due, H. Nørgaard, C.H. Perez-Andres, M. Samur, M.K. Davies, F. Walker, B. Pawlyn, C. Kaiser, M. Johnson, D. Bertsch, U. Broyl, A. van Duin, M. Shah, R. Johansen, P. Nørgaard, M.A. Samworth, R.J. Sonneveld, P. Goldschmidt, H. Morgan, G.J. Orfao, A. Munshi, N. Johnson, H.E. El-Galaly, T. Dybkær, K. Bøgsted, M. (2018). A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood adv, Vol.2 (18), pp. 2400-2411.  show abstract  full text

Boyle, E.M. Ashby, C. Wardell, C.P. Rowczenio, D. Sachchithanantham, S. Wang, Y. Johnson, S.K. Bauer, M.A. Weinhold, N. Kaiser, M.F. Johnson, D.C. Jones, J.R. Pawlyn, C. Proszek, P. Schinke, C. Facon, T. Dumontet, C. Davies, F.E. Morgan, G.J. Walker, B.A. Wechalekar, A.D. (2018). The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, Vol.132 (26), pp. 2775-2777.  full text

Johnson, D.C. Lenive, O. Mitchell, J. Jackson, G. Owen, R. Drayson, M. Cook, G. Jones, J.R. Pawlyn, C. Davies, F.E. Walker, B.A. Wardell, C. Gregory, W.M. Cairns, D. Morgan, G.J. Houlston, R.S. Kaiser, M.F. (2017). Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, Vol.130 (14), pp. 1639-1643.  show abstract  full text

Rasche, L. Angtuaco, E. McDonald, J.E. Buros, A. Stein, C. Pawlyn, C. Thanendrarajan, S. Schinke, C. Samant, R. Yaccoby, S. Walker, B.A. Epstein, J. Zangari, M. van Rhee, F. Meissner, T. Goldschmidt, H. Hemminki, K. Houlston, R. Barlogie, B. Davies, F.E. Morgan, G.J. Weinhold, N. (2017). Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood, Vol.130 (1), pp. 30-34.  show abstract  full text

Tumber, A. Nuzzi, A. Hookway, E.S. Hatch, S.B. Velupillai, S. Johansson, C. Kawamura, A. Savitsky, P. Yapp, C. Szykowska, A. Wu, N. Bountra, C. Strain-Damerell, C. Burgess-Brown, N.A. Ruda, G.F. Fedorov, O. Munro, S. England, K.S. Nowak, R.P. Schofield, C.J. La Thangue, N.B. Pawlyn, C. Davies, F. Morgan, G. Athanasou, N. Müller, S. Oppermann, U. Brennan, P.E. (2017). Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell chem biol, Vol.24 (3), pp. 371-380.  show abstract

Pawlyn, C. Morgan, G.J. (2017). Evolutionary biology of high-risk multiple myeloma. Nat rev cancer, Vol.17 (9), pp. 543-556.  show abstract

Stein, C.K. Pawlyn, C. Chavan, S. Rasche, L. Weinhold, N. Corken, A. Buros, A. Sonneveld, P. Jackson, G.H. Landgren, O. Mughal, T. He, J. Barlogie, B. Bergsagel, P.L. Davies, F.E. Walker, B.A. Morgan, G.J. (2017). The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget, Vol.8 (17), pp. 27854-27867.  show abstract

Pawlyn, C. Bright, M.D. Buros, A.F. Stein, C.K. Walters, Z. Aronson, L.I. Mirabella, F. Jones, J.R. Kaiser, M.F. Walker, B.A. Jackson, G.H. Clarke, P.A. Bergsagel, P.L. Workman, P. Chesi, M. Morgan, G.J. Davies, F.E. (2017). Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood cancer j, Vol.7 (3), p. e549.  show abstract  full text

Pawlyn, C. Kaiser, M.F. Heuck, C. Melchor, L. Wardell, C.P. Murison, A. Chavan, S.S. Johnson, D.C. Begum, D.B. Dahir, N.M. Proszek, P.Z. Cairns, D.A. Boyle, E.M. Jones, J.R. Cook, G. Drayson, M.T. Owen, R.G. Gregory, W.M. Jackson, G.H. Barlogie, B. Davies, F.E. Walker, B.A. Morgan, G.J. (2016). The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin cancer res, Vol.22 (23), pp. 5783-5794.  show abstract  full text

Wale, A. Pawlyn, C. Kaiser, M. Messiou, C. (2016). Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. Haematologica, Vol.101 (4), pp. e142-e144.

Pawlyn, C. Fowkes, L. Otero, S. Jones, J.R. Boyd, K.D. Davies, F.E. Morgan, G.J. Collins, D.J. Sharma, B. Riddell, A. Kaiser, M.F. Messiou, C. (2016). Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. Leukemia, Vol.30 (6), pp. 1446-1448.

Pawlyn, C. Gay, F. Larocca, A. Roy, V. Ailawadhi, S. (2016). Nuances in the Management of Older People With Multiple Myeloma. Curr hematol malig rep, Vol.11 (3), pp. 241-251.  show abstract

Jones, J.R. Cairns, D.A. Gregory, W.M. Collett, C. Pawlyn, C. Sigsworth, R. Striha, A. Henderson, R. Kaiser, M.F. Jenner, M. Cook, G. Russell, N.H. Williams, C. Pratt, G. Kishore, B. Lindsay, J. Drayson, M.T. Davies, F.E. Boyd, K.D. Owen, R.G. Jackson, G.H. Morgan, G.J. (2016). Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer j, Vol.6 (12), p. e506.  show abstract  full text

Jones, J.R. Pawlyn, C. Davies, F.E. Morgan, G.J. (2016). The safety of pomalidomide for the treatment of multiple myeloma. Expert opin drug saf, Vol.15 (4), pp. 535-547.  show abstract

Otero, S. Kaiser, M. Pawlyn, C. Giles, S. Scurr, E. Messiou, C. (2015). Patient experience of whole body diffusion weighted magnetic resonance imaging (WB-MRI) for staging myeloma. Cancer imaging : the official publication of the international cancer imaging society, Vol.15 (Suppl 1), pp. P13-P13.

Walker, B.A. Boyle, E.M. Wardell, C.P. Murison, A. Begum, D.B. Dahir, N.M. Proszek, P.Z. Johnson, D.C. Kaiser, M.F. Melchor, L. Aronson, L.I. Scales, M. Pawlyn, C. Mirabella, F. Jones, J.R. Brioli, A. Mikulasova, A. Cairns, D.A. Gregory, W.M. Quartilho, A. Drayson, M.T. Russell, N. Cook, G. Jackson, G.H. Leleu, X. Davies, F.E. Morgan, G.J. (2015). Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J clin oncol, Vol.33 (33), pp. 3911-3920.  show abstract

Walker, B.A. Wardell, C.P. Murison, A. Boyle, E.M. Begum, D.B. Dahir, N.M. Proszek, P.Z. Melchor, L. Pawlyn, C. Kaiser, M.F. Johnson, D.C. Qiang, Y.-. Jones, J.R. Cairns, D.A. Gregory, W.M. Owen, R.G. Cook, G. Drayson, M.T. Jackson, G.H. Davies, F.E. Morgan, G.J. (2015). APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat commun, Vol.6, p. 6997.  show abstract

Pawlyn, C. Melchor, L. Murison, A. Wardell, C.P. Brioli, A. Boyle, E.M. Kaiser, M.F. Walker, B.A. Begum, D.B. Dahir, N.B. Proszek, P. Gregory, W.M. Drayson, M.T. Jackson, G.H. Ross, F.M. Davies, F.E. Morgan, G.J. (2015). Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, Vol.125 (5), pp. 831-840.  show abstract

Pawlyn, C. Kaiser, M.F. Davies, F.E. Morgan, G.J. (2014). Current and potential epigenetic targets in multiple myeloma. Epigenomics, Vol.6 (2), pp. 215-228.  show abstract

Pawlyn, C. Hookway, E. Cain, P. Pliuskys, L. Kaiser, M.F. Bright, M. Aronson, L.I. Murison, A. Lindow, M. Obad, S. Oerum, H. Opperman, U. Morgan, G.J. Davies, F.E. (2014). Histone Demethylase Inhibition As a Novel Therapeutic Strategy in Myeloma. Blood, Vol.124 (21).

Pawlyn, C. Khan, M.S. Muls, A. Sriskandarajah, P. Kaiser, M.F. Davies, F.E. Morgan, G.J. Andreyev, H.J. (2014). Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood, Vol.124 (15), pp. 2467-2468.

Brioli, A. Melchor, L. Titley, I. Vijayaraghavan, G. Stephens, C. Zeisig, A. Pawlyn, C. Cavo, M. Morilla, R. Davies, F.E. Morgan, G.J. (2014). The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. Leuk lymphoma, Vol.55 (11), pp. 2665-2668.

Brioli, A. Giles, H. Pawlyn, C. Campbell, J.P. Kaiser, M.F. Melchor, L. Jackson, G.H. Gregory, W.M. Owen, R.G. Child, J.A. Davies, F.E. Cavo, M. Drayson, M.T. Morgan, G.J. (2014). Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, Vol.123 (22), pp. 3414-3419.  show abstract

Mirabella, F. Murison, A. Aronson, L.I. Wardell, C.P. Thompson, A.J. Hanrahan, S.J. Fok, J.H. Pawlyn, C. Kaiser, M.F. Walker, B.A. Davies, F.E. Morgan, G.J. (2014). A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. Plos one, Vol.9 (6), p. e99493.  show abstract

Brioli, A. Boyd, K.D. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. Br j haematol, Vol.161 (2), pp. 291-294.

Brioli, A. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk lymphoma, Vol.54 (9), pp. 1975-1981.  show abstract

Nagendran, S.T. Pawlyn, C. Brown, M. Pelosini, L. (2012). Crystalline keratopathy associated with monoclonal gammopathy of undetermined significance. Br j haematol, Vol.159 (3), p. 258.

Boyd, K.D. Pawlyn, C. Morgan, G.J. Davies, F.E. (2012). Understanding the molecular biology of myeloma and its therapeutic implications. Expert rev hematol, Vol.5 (6), pp. 603-617.  show abstract


Conferences

Eccleston, M.E.Williams, S.L.Yue, Z.Chen, R.Lee, C.K.Anikina, E.Pawlyn, C.Barrand, M.A.Slater, N.K. (2005). Design and in-vitro testing of effective poly(L-lysine iso-phthalamide) based drug targeting systems for solid tumours., Food and bioproducts processing., Vol.83, pp.141-146.

In this section

Publications